Introduction The ophthalmic (eye-care) landscape is currently undergoing its most significant regulatory and therapeutic transformation in a decade. As the FDA moves away from retrospective, probabilistic testing toward a proactive Quality Revolution, the criteria for market entry have fundamentally shifted. Sponsors are now tasked with balancing hyper-speed innovation—such as the "biosimilar tsunami" and the explosion [...]